Cantor Fitzgerald reiterates Overweight on Zai Lab stock at USD 37.00 target

Published on 10/07/2026 at 03:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zai Lab stock won an Overweight rating on October 6, 2026. Second-quarter revenue hit USD 106.31 million versus USD 104.34 million consensus.

ZLAB, US98887Q1040, Illustration mit AI erstellt.

Zai Lab Limited (ISIN US98887Q1040) has a fresh analyst catalyst: According to Investing.com on October 6, 2026, Cantor Fitzgerald reiterated an Overweight rating and a USD 37.00 price target. The report placed attention on zocilurtatug, Zai Lab's DLL3 antibody-drug conjugate for small cell lung cancer.

Revenue beats the consensus

Investing.com reported that Zai Lab generated USD 106.31 million in revenue in the second quarter of 2026, above the USD 104.34 million consensus estimate. Adjusted earnings per share were a loss of USD 0.05, compared with a consensus loss of USD 0.60, while the company reported a USD 50.83 million net loss for the period.

The comparison matters because revenue growth alone does not yet translate into profitability. Zai Lab's second-quarter cash and cash equivalents stood at USD 607.52 million, while operating cash flow was negative USD 63.41 million, according to the reported financial statements for the period.

Zocilurtatug reaches a key data date

In a September 29, 2026 release, Zai Lab said it will present first global data from a trial evaluating zocilurtatug with atezolizumab, with or without carboplatin, in first-line extensive-stage small cell lung cancer. The ESMO Congress is scheduled for October 23 to October 27, 2026, and the company scheduled an investor call for October 23, 2026.

For investors, the upcoming readout is the measurable test behind the analyst view. Cantor Fitzgerald said response rates of 70.00 percent to 80.00 percent and median progression-free survival of seven months are already reflected in expectations, while results above eight months could support further upside, as reported by Investing.com on October 6, 2026.

NASDAQ valuation and trading context

Zai Lab's primary listing is NASDAQ, where ZLAB was trading at USD 25.58 on October 6, 2026 at 4:00 p.m. ET. The same quote showed a USD 15.96 to USD 33.97 52-week range and a USD 2.9 billion market capitalization, placing the latest primary-exchange price 24.75 percent below the yearly high.

The last Lang & Schwarz close was EUR 22.70 on October 6, 2026, with the venue's previous-close value serving as the euro reference for German-market investors. The further course of trading is shown by the continuously updated real-time quote of Zai Lab stock.